Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MannKind (NASDAQ: MNKD ) is scheduled to release data for two phase 3 trials of its inhaled insulin, Afrezza, this month.
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive. I'll be shocked if both trials don't meet their endpoints.
Why the clinical trials will be positive
Simply put, there isn't that much difference between the product MannKind studied in its previous successful phase 3 trials and the device used in its current trials, Affinity 1 and Affinity 2.
The new inhaler, dubbed Dream Boat, is smaller than MedTone, but there's little reason to think the underlying insulin will do anything differently once it enters the body.
http://www.fool.com/investing/general/2013/08/09/the-easiest-prediction-in-biotech-this-summer.aspx
Eh? Fast acting insulin produces lower fasting levels? Say what? 🙄 Does any of the above make any sense to anyone?
Nothing is for certain in biotech, but it looks to me like the extended phase 3 program has an extremely high likelihood of coming up positive. I'll be shocked if both trials don't meet their endpoints.
Why the clinical trials will be positive
Simply put, there isn't that much difference between the product MannKind studied in its previous successful phase 3 trials and the device used in its current trials, Affinity 1 and Affinity 2.
The new inhaler, dubbed Dream Boat, is smaller than MedTone, but there's little reason to think the underlying insulin will do anything differently once it enters the body.
http://www.fool.com/investing/general/2013/08/09/the-easiest-prediction-in-biotech-this-summer.aspx
MannKind thinks part of the reason why its A1C levels don't look quite as good stems from the way the two products change blood sugar levels. Rapid-acting injected insulins, such as Novo Nordisk's (NYSE: NVO ) NovoLog and Eli Lilly's (NYSE: LLY ) Humalog, tend to produce lower fasting blood sugar levels compared to Afrezza. Hypoglycemia -- low blood sugar levels -- is extremely dangerous, so the long-acting insulin that diabetics also use is adjusted so the patient's blood sugar level is high enough that the lows between meals don't become too low.
Since the fasting lows aren't nearly as low for patients taking Afrezza, patients can start with lower blood sugar levels. To produce parity, patients in the Affinity 1 trial are required to reduce their blood sugar level to a certain level before Afrezza or the rapid-acting insulin is tested.
Eh? Fast acting insulin produces lower fasting levels? Say what? 🙄 Does any of the above make any sense to anyone?